My buddy sells software to bariatric clinics and he's telling me that the era is OVER.
Surgeries are down 40-50+% due to ozempic. The same demographic that can afford surgery can afford ozempic instead.
It's going to be really interesting to watch the ripple effects of this. https://t.co/MWaJLIfVqY
I wrote about the new anti-obesity drugs—semaglutide (Wegovy) and tirzepatide (Mounjaro)—that represent one of the most important breakthroughs in medicine
https://t.co/SMZO20ExDk